That's what I'm saying,..the case/controls were not set up properly, so your point is what you called my point,...nonsense.
Your second point is tough to fathom too, because most patients with arthritis with severe enough pain to warrant taking a pain relief drug chronically are using a NSAID, so you are not at this time likely to find a group that is NSAID free that you could use as your control.
Your third point about taking a bet that all Cox-2's are the same physiologically,...maybe they are, maybe they aren't, but Pharmacia says they aren't so place your bet with them. You are not so good at winning bets so I suggest you stop making them (gggggggggggg)
This comes from the current letter to shareholders of Dimethaid confirming that what I suggested the FDA was concerned about 3 years ago was exactly what they were concerned about. I am right again.
The new board has learned that in August 2002, the U.S. Food and Drug
Administration sent the company a complete response letter recommending
additional efficacy and long-term safety data, along with an extra,
pharmacokinetic study providing more information about how the drug is
absorbed and eliminated from the body. |
